Skip to content
Medical Health Aged Care

CTE funding set to boost Australia’s future brain health

Dementia Australia 2 mins read

Dementia Australia welcomes the $12.5 million investment by the Federal Government to tackle chronic traumatic encephalopathy (CTE), announced in Brisbane today by the Hon. Anika Wells MP, Minister for Aged Care and Minister for Sport.

Dementia Australia CEO Professor Tanya Buchanan said with this funding, Dementia Australia, together with the Concussion and CTE Coalition and other important partners, and working with the Federal Government, will develop and deliver a national pilot program of support services for people impacted by CTE, and a national awareness and education program in schools.

“CTE is a preventable form of dementia, and some estimates suggest thousands of people are impacted,” Professor Buchanan said.

“As dementia edges close to becoming the leading cause of death of Australians, it is crucial we act now to focus on the brain health of the nation.

“Dementia Australia has been working closely with the Concussion and CTE Coalition and other partners advocating for support services, education and awareness raising about concussion and CTE.

“We acknowledge the generous support and commitment by Wally Lewis AM – a Dementia Australia and Connecters Australia Ambassador – who has been diagnosed with probable CTE. As Wally has said publicly many times: “We only get one brain.”

“We also wish to acknowledge the delegation of 20 people living with probable CTE and carers who joined the campaign in Federal Parliament in February last year to support the call for government support.”

CTE, as a form dementia, can result in changes in mood, personality, behaviour and cognitive function. Research has increasingly identified a strong causal link between repeated head injuries and CTE.  

Wally Lewis AM, Dementia Australia and Connecters Australia Ambassador said this funding was fantastic news. 

“On behalf of all people impacted by CTE I say thank you,” Mr Lewis said. 

“We need to be talking to the whole community about protecting our brains and brain health and continuing to support people who are impacted by the effects of repeated head injury and are at risk of CTE.”

The Concussion and CTE Coalition includes Dementia Australia, Brain Foundation, Connecters Australia, Associate Professor Fatima Nasrallah of the Queensland Brain Institute at The University of Queensland and Dr Rowena Mobbs of Queensland Brain Institute, University of Queensland.

-Ends-

Dementia Australia is the source of trusted information, education and services for the estimated more than 433,000 Australians living with dementia, and the more than 1.6 million people involved in their care. We advocate for positive change and support vital research. We are here to support people impacted by dementia, and to enable them to live as well as possible. No matter how you are impacted by dementia or who you are, we are here for you.

For support, please contact the National Dementia Helpline on 1800 100 500. An interpreter service is available. The National Dementia Helpline is funded by the Australian Government. People looking for information can also visit dementia.org.au

Media contacts: Gabrielle Prabhu, 0403 177 154 [email protected]

When talking or writing about dementia please refer to Dementia-Friendly Language Guidelines.

Note to Editors:

We request, where possible, details for the National Dementia Helpline 1800 100 500 appear alongside news stories about dementia, as these stories often prompt questions or concerns:

If this story has prompted any questions or concerns, please call the National Dementia Helpline 1800 100 500 (24 hours, 7 days a week) or visit dementia.org.au. 

Media

More from this category

  • Medical Health Aged Care
  • 18/12/2025
  • 22:11
BeOne Medicines Ltd.

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma

BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancer FDA Fast Track Designation reflects the…

  • Contains:
  • Medical Health Aged Care
  • 18/12/2025
  • 19:11
Takeda Pharmaceutical Company Limited

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half…

  • Contains:
  • Medical Health Aged Care
  • 18/12/2025
  • 12:24
La Trobe University

Cell death discovery could aid cancer treatments

LaTrobe researchers have made a groundbreaking discovery about the way dying cells are cleared from our bodies, which could have important impacts on recovery from diseases including cancer infection and inflammatory diseases. Traditionally, it was believed dying cells were broken into smaller pieces by the cell’s own internal machinery, enabling the pieces to be more easily removed from the body. However the study, led by scientists at the La Trobe Institute for Molecular Science and Research Centre for Extracellular Vesicles found that the process of dying cell fragmentation is actually assisted by neighbouring cells. Published in Science Advances, the study…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.